Involvement of portosystemic shunts in impaired improvement of liver function after direct-acting antivirals therapies in cirrhotic patients with hepatitis C virus.
Factors responsible for impaired improvement of liver function despite SVR after DAA therapies in cirrhotic patients with HCV needed to be elucidated. The liver function and extent of portosystemic shunting were evaluated in 79 patients with compensated cirrhosis, in whom SVR had been achieved after DAA therapies for HCV at least 3 years earlier. Portosystemic shunts were observed in 63 patients (80%). Improvement and worsening, as compared to the baseline, of esophageal/gastric varices after DAA therapies was seen in 3 patients (4%) and 10 patients (13%), respectively. Portal hypertension-related events, such as varices and ascites requiring treatment, were observed in 6 patients (8%), in whom 3 patients showing worsening of Child-Pugh scores were included. Multivariate analysis revealed that maximal diameter of the shunts (P=0.012) and serum M2BPGi levels at the end of treatment (P=0.005) were associated with the development of portal hypertension-related events, with cutoff values of 5.25 mm (P=0.001) and 6.84 C.O.I. (P<0.001), respectively. The increase of serum albumin levels at 3 years, as compared to the baseline, was smaller in 22 patients having shunts with maximal diameters of ≥5 mm than in the remaining 57 patients (P=0.034), while no such difference was seen between the patients with and without elevation of serum M2BPGi level of ≥6.8 C.O. A large size of portosystemic shunts was found to be a crucial determinant of impaired improvement of liver function as well as of the development of portal hypertension-related events, even after SVR in patients with compensated cirrhosis.